Shi Songxuan, Lu Mei, Huang Yuanyu
School of Life Science, Advanced Research Institute of Multidisciplinary Science, Aerospace Center Hospital, Key Laboratory of Molecular Medicine and Biotherapy, Key Laboratory of Medical Molecule Science and Pharmaceutics Engineering, Beijing Institute of Technology, Beijing, China.
School of Life Science, Advanced Research Institute of Multidisciplinary Science, Beijing Institute of Technology, Zhuhai, China.
Methods Mol Biol. 2025;2965:377-401. doi: 10.1007/978-1-0716-4742-4_19.
Lipid nanoparticles (LNPs) are among the most effective nanocarriers for siRNA delivery due to their high transfection efficiency, nucleic acid encapsulation capacity, and relatively low toxicity. This has led to significant interest from academic institutions and pharmaceutical companies. However, the intrinsic hepatic tropism of LNPs limits their potential for targeted siRNA delivery to tumors. Extracellular vesicles (EVs), as natural nucleic acid carriers, exhibit unique biological properties. In recent years, EVs derived from M1 macrophages have gained particular attention for tumor-targeted therapy. Bioinspired nanovesicles composed of LNPs and M1 macrophage-derived EVs may combine the advantageous characteristics of both carriers and offer a promising vehicle for siRNA delivery to tumor tissues, thus warranting further investigation. This chapter outlines a laboratory-scale method for constructing bioinspired nanovesicles. First, a range of experimental methods for screening and optimizing these nanovesicles are introduced. Then, various assessment metrics such as siRNA encapsulation efficiency, vesicle fusion efficiency, and target gene silencing efficiency are discussed. Finally, experimental designs are presented for evaluating the potential siRNA delivery capabilities of these bioinspired nanovesicles both in vitro and in vivo.
脂质纳米颗粒(LNPs)因其高转染效率、核酸包封能力和相对较低的毒性,成为用于小干扰RNA(siRNA)递送的最有效纳米载体之一。这引起了学术机构和制药公司的极大兴趣。然而,LNPs固有的肝靶向性限制了其将siRNA靶向递送至肿瘤的潜力。细胞外囊泡(EVs)作为天然核酸载体,具有独特的生物学特性。近年来,源自M1巨噬细胞的EVs在肿瘤靶向治疗中受到特别关注。由LNPs和源自M1巨噬细胞的EVs组成的仿生纳米囊泡可能兼具两种载体的优势特性,为将siRNA递送至肿瘤组织提供了一种有前景的载体,因此值得进一步研究。本章概述了一种构建仿生纳米囊泡的实验室规模方法。首先,介绍了一系列用于筛选和优化这些纳米囊泡的实验方法。然后,讨论了各种评估指标,如siRNA包封效率、囊泡融合效率和靶基因沉默效率。最后,给出了用于评估这些仿生纳米囊泡在体外和体内潜在siRNA递送能力的实验设计。